Jodi Daniel joins Crowell & Moring LLP

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JODI DANIEL joined the firm Crowell & Moring LLP as a partner in its Health Care Group.

Daniel is the former director of the Office of Policy in the Office of the National Coordinator for Health Information Technology at the Department of Health and Human Services. Daniel served for a decade as the director at the ONC and 15 years at HHS, where she worked on changes in health information privacy and health information technology.

As the first senior counsel for health information technology in the Office of the General Counsel of HHS, Daniel developed HHS’s foundational legal strategies and coordinated all legal advice regarding health IT for HHS.

“Jodi literally wrote the book—and all the rules— governing health information technology, including the complex HIPAA privacy and enforcement rules,” said John Brennan, Jr., chair of the firm’s Health Care Group. “Her experience in setting the regulatory framework and policies for both technology providers and adopters has supported innovation in areas including mobile health, remote devices and telehealth, and that insight will be of enormous value to our clients as they operate in this highly regulated space.”

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login